Published in Zhonghua Zhong Liu Za Zhi on March 01, 2001
Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci U S A (2001) 5.83
Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro. J Virol (1992) 3.44
A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. JAMA (1993) 2.60
Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli. J Virol (1988) 2.09
Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc Natl Acad Sci U S A (1989) 1.81
In vitro evidence for homologous recombinational repair in resistance to melphalan. J Natl Cancer Inst (2001) 1.65
Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release. J Virol (2003) 1.56
Expression in Escherichia coli and purification of human immunodeficiency virus type 1 capsid protein (p24). AIDS Res Hum Retroviruses (1990) 1.40
HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro: structure switching by pH-induced conformational changes. Biophys J (2001) 1.32
Liquid and solid potassium chloride: bioavailability and safety. Pharmacotherapy (1985) 1.21
Membrane-induced alterations in HIV-1 Gag and matrix protein-protein interactions. J Mol Biol (1998) 1.17
Release of N2,3-ethanoguanine from haloethylnitrosourea-treated DNA by Escherichia coli 3-methyladenine DNA glycosylase II. Carcinogenesis (1991) 1.14
Preparation and crystallization of a human immunodeficiency virus p24-Fab complex. Proc Natl Acad Sci U S A (1990) 1.13
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol (2013) 1.11
The major homology region of the HIV-1 gag precursor influences membrane affinity. Biochemistry (1996) 1.07
Direct interaction of all-trans-retinoic acid with protein kinase C (PKC). Implications for PKC signaling and cancer therapy. J Biol Chem (2000) 1.05
Comparison of models describing the thermal lens effect. Appl Opt (1984) 1.04
Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res (1983) 1.02
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. Br J Cancer (2011) 1.02
Evidence for nucleotide excision repair as a modifying factor of O6-methylguanine-DNA methyltransferase-mediated innate chloroethylnitrosourea resistance in human tumor cell lines. Mol Pharmacol (1997) 1.01
Review of diclofenac and evaluation of its place in therapy as a nonsteroidal antiinflammatory agent. Drug Intell Clin Pharm (1988) 1.00
Cyclophilin A-induced alterations of human immunodeficiency virus type 1 CA protein in vitro. J Virol (1997) 0.99
Spectral analysis and tryptic susceptibility as probes of HIV-1 capsid protein structure. Virology (1994) 0.98
Requirement of essential fatty acid for mammary tumorigenesis in the rat. Cancer Res (1985) 0.97
Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents. Cancer Res (1993) 0.93
Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol (2009) 0.91
Methylation of reovirus oligonucleotides in vivo and in vitro. Virology (1977) 0.90
Evaluation of the effectiveness of two support surfaces following myocutaneous flap surgery. Adv Wound Care (1995) 0.90
Corneal cell culture and organ storage. Trans Ophthalmol Soc U K (1986) 0.90
Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia. Clin Cancer Res (1999) 0.87
A consensus conference on complex biologics and low molecular weight heparins. Int Angiol (2010) 0.86
Characterization of L-threonine and L-glutamine transport in murine P388 leukemia cells in vitro. Presence of an N-like amino acid transport system. Biochim Biophys Acta (1986) 0.85
A structure-activity analysis of chemical and biological parameters of chloroethylnitrosoureas in mice. Cancer Res (1977) 0.84
Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system. Mol Pharmacol (1993) 0.84
Trastuzumab and vinorelbine in early stages of HER2-positive breast cancer. J Chemother (2011) 0.83
Release of 7-alkylguanines from N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea-modified DNA by 3-methyladenine DNA glycosylase II. Cancer Res (1991) 0.83
Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry (2001) 0.82
Experimental ulcerative herpetic keratitis. IV. Preliminary observations on the efficacy of a herpes simplex subunit vaccine. Br J Ophthalmol (1981) 0.82
Formation and Reactivity of the Osmium(IV)-Cyanoimido Complex [Os(IV) (bpy)(Cl)3 (NCN)](-). Angew Chem Int Ed Engl (2001) 0.82
2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. Cancer Res (1997) 0.81
Effects of amino acids on the transport and cytotoxicity of melphalan by human bone marrow cells and human tumor cells. Cancer Chemother Pharmacol (1985) 0.81
Stimulation of CD4+ T lymphocytes by allogeneic MHC peptides presented on autologous antigen-presenting cells. Evidence of the indirect pathway of allorecognition in some strain combinations. Transplantation (1992) 0.81
Sprouty 2 binds ESCRT-II factor Eap20 and facilitates HIV-1 gag release. J Virol (2011) 0.81
Ascorbic acid promotes recovery of cellular functions following toxicant-induced injury. Toxicol Appl Pharmacol (2000) 0.81
Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice. J Clin Invest (1979) 0.80
A rat class I cDNA clone with an Alu-like sequence and mapping to two genes in RT1.C/E. Immunogenetics (1990) 0.80
DNA repair enzyme expression in chronic lymphocytic leukemia vis-à-vis nitrogen mustard drug resistance. Cancer Lett (1995) 0.80
Identification of a 116 kDa protein able to bind 1,3-bis(2-chloroethyl)-1-nitrosourea-damaged DNA as poly(ADP-ribose) polymerase. Mutat Res (1996) 0.79
Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. Can J Neurol Sci (1999) 0.79
Biological activity, binding, and metabolic fate of Ac-[Nle4, D-Phe7]alpha-MSH4-11NH2 with the F1 variant of B16 melanoma cells. J Cell Physiol (1987) 0.79
Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance. Mutat Res (1995) 0.79
Phenotype and differentiation potential of a novel rat tracheal epithelial cell line. Am J Respir Cell Mol Biol (1995) 0.79
Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model. J Neurooncol (1999) 0.79
Phase II trial of carboplatin in advanced breast carcinoma: a Cancer and Leukemia Group B Study. Cancer Treat Rep (1985) 0.79
Conservation and modification of the pyrimidine-rich reovirus oligonucleotides after infection. Virology (1979) 0.79
Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics. Cancer Res (1994) 0.79
Extraneuronal monoamine transporter expression and DNA repair vis-à-vis 2-chloroethyl-3-sarcosinamide-1-nitrosourea cytotoxicity in human tumor cell lines. Clin Cancer Res (1999) 0.78
Biological and biochemical properties of 1-(2-chloroethyl)-3-(beta-D-glucopyranosyl)-1-nitrosourea (NSC D 254157), a nitrosourea with reduced bone marrow toxicity. Cancer Res (1977) 0.78
Both extraneuronal monoamine transporter and O(6)-methylguanine-DNA methyltransferase expression influence the antitumor efficacy of 2-chloroethyl-3-sarcosinamide- 1-nitrosourea in human tumor xenografts. J Pharmacol Exp Ther (2001) 0.78
Ethotoin in seizures of childhood and adolescence. Neurology (1984) 0.78
Polyethyleneimine grafted with pluronic P85 enhances Ku86 antisense delivery and the ionizing radiation treatment efficacy in vivo. Gene Ther (2004) 0.78
Tamoxifen alters the localization of F-actin and alpha 5/beta 1-integrin fibronectin receptors in human endometrial stromal cells and carcinoma cells. Pathobiology (1997) 0.78
Drug Information Center network: need, effectiveness, and cost justification. Drug Intell Clin Pharm (1987) 0.78
A phenol technique for extraction of alkylated DNA, RNA, and protein from a single tissue sample. Anal Biochem (1977) 0.78
Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer. Drug Intell Clin Pharm (1986) 0.78
Structure-activity studies of methylnitrosourea antitumor agents with reduced murine bone marrow toxicity. Cancer Res (1977) 0.78
T-cell recognition of an allogeneic RT1-Dbu class II MHC peptide. Immunol Lett (1994) 0.77
In vitro comparative studies of the myelotoxicity and antitumor activity of 6-[bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose versus melphalan utilizing the CFU-C and HTSCA assays. Cancer Chemother Pharmacol (1986) 0.77
Polyadenylylation of reovirus proteins. Analysis of the RNA bound to structural proteins. J Biol Chem (1980) 0.77
Evidence for increased alpha MSH receptor binding in the F1 variant of B16 melanoma cells grown in dialyzed fetal calf serum. J Cell Physiol (1989) 0.77
Quantitation of ERCC-2 gene expression in human tumor cell lines by reverse transcription-polymerase chain reaction in comparison to northern blot analysis. Anal Biochem (1997) 0.77
The rat RT.BM1 MHC class I cDNA shows a high level of sequence similarity to the mouse H-2T23d gene. Immunogenetics (1991) 0.76
Polyadenylylation of proteins in reovirions. Proc Natl Acad Sci U S A (1979) 0.76
Effect of pH and nonphysiological salt concentrations on human immunodeficiency virus-1 protease dimerization. Biochem Cell Biol (1995) 0.76
Excision repair cross-complementing rodent repair deficiency gene 2 expression and chloroethylnitrosourea resistance in human glioma cell lines. Neurosurgery (1998) 0.76
Multiple cellular proteins are recognized by the adeno-associated virus Rep78 major regulatory protein and the amino-half of Rep78 is required for many of these interactions. Biochem Mol Biol Int (1997) 0.76
Comparison of tissue factor pathway in human umbilical vein and adult saphenous vein endothelial cells: implications for newborn hemostasis and for laboratory models of endothelial cell function. Pediatr Res (1999) 0.76
Clodronate in metastatic breast cancer. N Engl J Med (1998) 0.76
Re: five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst (1997) 0.75
Effects of retinoic acid combined with interferon-gamma on the expression of major-histocompatibility-complex molecules and intercellular adhesion molecule-1 in human cervical cancer. Int J Cancer (1998) 0.75
Experimental ulcerative herpetic keratitis. II. Influence of topical corticosteroid in immunised rabbits. Br J Ophthalmol (1981) 0.75
Aromatase inhibitors: treatment of advanced breast cancer. J Clin Oncol (2001) 0.75
Experimental ulcerative herpetic keratitis. III. Evaluation of hyperimmune gammaglobulin therapy. Br J Ophthalmol (1981) 0.75
Lack of evidence for a high-affinity sarcosinamide carrier or a catecholamine carrier in Calu-1 lung-cancer cells, HT-29 colon-cancer cells, and DHF fibroblasts. Cancer Chemother Pharmacol (1992) 0.75
Correlation of chloroethylnitrosourea resistance with ERCC-2 expression in human tumor cell lines as determined by quantitative competitive polymerase chain reaction. Cancer Res (1996) 0.75
Characterization of the catecholamine extraneuronal uptake2 carrier in human glioma cell lines SK-MG-1 and SKI-1 in relation to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) selective cytotoxicity. Biochem Pharmacol (1996) 0.75
Localization of tenascin in uterine sarcomas and partially transformed endometrial stromal cells. Pathobiology (1993) 0.75
Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells. Mol Pharmacol (1990) 0.75
Balancing the clinical outcomes and economics associated with thromboembolic prophylaxis. Orthopedics (1996) 0.75
Clinical response of O(6)-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients. Neurosurg Focus (1998) 0.75
Safety and acid-suppressant properties of histamine2-receptor antagonists for the prevention of stress-related mucosal damage in critical care patients. DICP (1989) 0.75
The pharmacology of antiulcer drugs. DICP (1989) 0.75
Continuous assay of the hydrolytic activity of human immunodeficiency virus-1 protease. Anal Biochem (1992) 0.75
Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1. Cancer Chemother Pharmacol (1990) 0.75
The formation and enzymatic repair of DNA modifications caused by the haloethylnitrosoureas and related compounds. Nucleic Acids Symp Ser (1992) 0.75
[Anti-tumor efficacy of 2-chloroethyl-3-sarcosinamide-1-nitrosourea in a human lung cancer xenograft model with DNA repair gene expressions]. Zhongguo Fei Ai Za Zhi (2000) 0.75
Adjuvant therapy for breast cancer. N Engl J Med (1994) 0.75
Formation of N2,3-ethanoguanine in DNA after in vitro treatment with the therapeutic agent, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea. Carcinogenesis (1990) 0.75